| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
22,090,000 |
| Market
Cap: |
291.81(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.84 - $22.64 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile roGen Pharma is a biopharmaceutical company focused on developing and commercializing solutions that treat urothelial and specialty cancers. Co.'s approved product Jelmyto® (mitomycin) for pyelocalyceal solution, and its investigational candidate, UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively. In addition, Co.'s immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,000 |
29,564 |
33,364 |
41,023 |
| Total Sell Value |
$168,600 |
$445,409 |
$513,847 |
$580,710 |
| Total People Sold |
1 |
2 |
2 |
2 |
| Total Sell Transactions |
1 |
5 |
6 |
11 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barrett Elizabeth A. |
Chief Executive Officer |
• – – |
2020-05-03 |
4/A |
OE |
$0.00 |
$0 |
D/D |
8,808 |
157,465 |
|
- |
|
| Pfreundschuh Peter P. |
Chief Financial Officer |
• – – |
2020-04-27 |
4 |
S |
$24.35 |
$3,433 |
D/D |
(141) |
6,396 |
|
16% |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2020-04-27 |
4 |
S |
$24.35 |
$1,705 |
D/D |
(70) |
17,711 |
|
16% |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2020-04-27 |
4 |
S |
$24.35 |
$3,531 |
D/D |
(145) |
10,084 |
|
16% |
|
| Pfreundschuh Peter P. |
Chief Financial Officer |
• – – |
2020-04-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
417 |
6,537 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2020-04-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
208 |
17,781 |
|
- |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2020-04-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
417 |
10,229 |
|
- |
|
| Barrett Elizabeth A. |
Chief Executive Officer |
• – – |
2020-04-03 |
4/A |
OE |
$0.00 |
$0 |
D/D |
8,807 |
148,657 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2020-03-04 |
4 |
D |
$29.50 |
$10,178 |
D/D |
(345) |
17,573 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2020-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,042 |
17,918 |
|
- |
|
| Barrett Elizabeth A. |
Chief Executive Officer |
• – – |
2020-03-03 |
4/A |
OE |
$0.00 |
$0 |
D/D |
8,807 |
139,850 |
|
- |
|
| Pfreundschuh Peter P. |
Chief Financial Officer |
• – – |
2020-02-20 |
4 |
S |
$29.68 |
$10,685 |
D/D |
(360) |
6,120 |
|
14% |
|
| Pfreundschuh Peter P. |
Chief Financial Officer |
• – – |
2020-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,042 |
6,480 |
|
- |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2020-02-14 |
4 |
S |
$28.04 |
$17,160 |
D/D |
(612) |
9,812 |
|
5% |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2020-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,759 |
10,424 |
|
- |
|
| Barrett Elizabeth A. |
Chief Executive Officer |
• – – |
2020-02-03 |
4/A |
OE |
$0.00 |
$0 |
D/D |
8,807 |
131,043 |
|
- |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2020-01-27 |
4 |
S |
$29.26 |
$20,014 |
D/D |
(684) |
8,665 |
|
13% |
|
| Pfreundschuh Peter P. |
Chief Financial Officer |
• – – |
2020-01-27 |
4 |
S |
$29.28 |
$19,530 |
D/D |
(667) |
4,438 |
|
13% |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2020-01-27 |
4 |
S |
$29.15 |
$9,386 |
D/D |
(322) |
9,177 |
|
13% |
|
| Mullennix Stephen |
Chief Operating Officer |
• – – |
2020-01-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,666 |
9,349 |
|
- |
|
| Pfreundschuh Peter P. |
Chief Financial Officer |
• – – |
2020-01-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,666 |
5,105 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2020-01-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
833 |
9,499 |
|
- |
|
| Barrett Elizabeth A. |
Chief Executive Officer |
• – – |
2020-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
105,688 |
122,236 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2019-12-04 |
4 |
D |
$31.69 |
$10,870 |
D/D |
(343) |
8,666 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2019-12-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,042 |
9,009 |
|
- |
|
156 Records found
|
|
Page 5 of 7 |
|
|
0.57 (4.14%) 
